The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
Tislelizumab is now approved in nine indications in China
Subscribe To Our Newsletter & Stay Updated
